Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Novavax AB
AB
Active
Org 5565494019
Kungsgatan 109, 753 18
Uppsala
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 1997
173 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Novavax AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
452M
903M
1B
2B
395M
2020
981M
2021
1.6B
2022
820M
2023
525M
2024
EBITDA
SEK millions
0M
149M
297M
446M
595M
-12M
2020
-112M
2021
517M
2022
200M
2023
105M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
395 176
980 891
1 570 987
820 346
524 647
Staff expenses
—
—
—
—
—
EBITDA
−11 698
−111 547
517 253
200 182
104 765
Depreciation & amort.
—
—
—
—
—
EBIT
−11 698
−111 547
517 253
200 182
104 765
Net financials
−195 722
−379 103
−680 903
−601 390
155 510
Profit before tax
−11 703
−111 565
518 188
194 900
260 275
Tax
−0
−0
417
−5 605
−54 471
Net profit
−11 703
−111 565
518 605
189 295
205 804
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
2 573 297
3 593 711
3 747 809
3 615 737
2 654 994
Equity
1 311 696
1 513 380
2 086 642
2 296 795
2 517 637
Long-term debt
0
0
0
0
0
Short-term debt
1 261 601
2 080 331
1 661 167
1 318 942
131 064
Total debt
1 261 601
2 080 331
1 661 167
1 318 942
131 064
Financial ratios
5-year trend
EBITDA margin
20.0%
This company
15.8%
Market median
+27% vs market
2020
2024
Equity ratio
94.8%
This company
38.2%
Market median
+148% vs market
2020
2024
Return on equity
8.2%
This company
18.4%
Market median
-55% vs market
2020
2024
Net profit margin
39.2%
This company
8.1%
Market median
+384% vs market
2020
2024
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
2020
2024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Novavax AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
